Diosmin's usage in hemorrhoids treatment

 The first commercial launch of Diosmin was in 1971 in France under the brand name Daflon, containing micronized (finely ground) combination of diosmin (90%) and hesperidin (10%).

At this point began the most studied citrus bioflavonoid treatment which inspired with hope many hemorrhoids sufferers.

Diosmin is considered to be a vascular-protecting agent used to treat chronic venous insufficiency, hemorrhoids, lymphedema, and varicose veins.

Diosmin also exhibits anti-inflammatory and antimutagenic properties.

Double-blind trials suggest that a micronized combination preparation of diosmin and hesperidin may be helpful for hemorrhoids.

A hundred patients suffering an acute hemorrhoid attack received diosmin (90%) and hesperidin (10%) in a loading dose of three 500 mg tablets twice daily for the first four days and two tablets twice daily the following three days.

The clinical severity of anal discomfort, pain, and anal discharge diminished to a greater extent in the treatment group in comparison with placebo group.

A study of pregnant women suffering from acute hemorrhoids who were treated with Daflon/ diosmin (90%) and hesperidin (10%)/ showed that the treatment did not affect pregnancy, fetal development, birth weight, infant growth, or feeding.

At the same time half of the women reported relief from symptoms by the fourth day of treatment.

Daflon is however not readily available in the United States but its ingredients/ diosmin, hesperidin/ can be found in many dietary supplements.
Most of these supplemenets contain quantity of diosmin and hesperedine which is enough for treating hemorrhoids.

The standard dose of diosmin is 500 mg twice daily. For acute dosing, a loading dose of 1,000 mg three times daily for four days is recommended, followed by 1,000 mg twice daily for three days, and a maintenance dose of 500 mg twice daily for two months.

<< Previous    1  [2]  3    Next >>